Global Cancer Immunotherapy Market Opportunities 2024, Forecast To 2033
16 Feb, 2024
The cancer immunotherapy market has rapidly expanded, surging from $97.88 billion in 2023 to $110.91 billion in 2024, reflecting a 13.3% CAGR. Historical growth is attributed to increased cancer prevalence, immunotherapy adoption, R&D for targeted diseases, improved therapy efficacy, and recognition of traditional treatment limitations. Expected to maintain a rapid pace, the market is forecasted to reach $175.39 billion in 2028, fueled by novel immunotherapy approvals, personalized medicine demand, rising cancer cases, increased clinical trial investments, and heightened awareness. Key trends include adoptive cell therapies, oncolytic viruses, personalized cancer vaccines, AI in research, and emphasis on real-world evidence.
Global Cancer Immunotherapy Market Key Driver
The rise in cancer incidence is expected to propel the cancer immunotherapy market. Factors such as tobacco use, alcohol consumption, obesity, sedentary lifestyles, and environmental factors contribute to the increase in cancer cases globally. The rising incidence of cancer is expected to drive the demand for cancer immunotherapies as patients seek effective and less painful medical treatments. The data from the European Union Science Hub underscores the growth in new cancer cases, supporting the anticipated boost in the cancer immunotherapy market.
Get A Free Sample Of The Global Cancer Immunotherapy Market ReportGlobal Cancer Immunotherapy Market Segments
The cancer immunotherapy market covered in this report is segmented –
1) By Product: Monoclonal Antibodies, Checkpoint Inhibitors, Immunomodulators, Vaccines, Cell Therapy
2) By Application: Lung Cancer, Breast Cancer, Colorectal Cancer, Melanoma, Prostate Cancer, Multiple Myeloma
3) By End User: Hospitals, Cancer Research Centers, Clinics
By Geography: The regions covered in the template market report are Asia-Pacific, Western Europe, Eastern Europe,North America, South America, Middle East, and Africa. Among these regions.
North America was the largest region in the cancer immunotherapy market in 2023 and is also expected to be the fastest-growing region in the forecast period. The regions covered in the cancer immunotherapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Major Cancer Immunotherapy Industry Players
Amgen Inc.; AstraZeneca PLC; F. Hoffmann-La Roche Ltd; Bayer AG; Eli Lilly and Company; 3D Signatures Inc.; Adaptive Biotechnologies Corp.; Argos Therapeutics Inc.; Bristol-Myers Squibb Company; Cell Medica Limited; Cellular Biomedicine Group Inc.; Gilead Sciences Inc.; Gradalis Inc.; Immatics Biotechnologies GmbH; Iovance Biotherapeutics Inc.; Juno Therapeutics LLC; Kura Oncology Inc.; MacroGenics Inc.; Merck & Co. Inc.; Neon Therapeutics Inc.; Neovii Biotech GmbH; Novartis International AG; Pfizer Inc.; Pulse Biosciences Inc.; Regeneron Pharmaceuticals Inc.; Roche Holding AG; Targovax ASA; Tessa Therapeutics Pte Ltd.; TILT Biotherapeutics Ltd.; Turnstone Biologics Corp.; Xencor Inc.
Get The Full Global Cancer Immunotherapy Market Report
Cancer Immunotherapy Market Overview
Cancer immunotherapy refers to a type of cancer therapy that strengthens your body's defenses against the disease. Your body's immune system aids in the defense against infections and other disorders. White blood cells, organs, and lymphatic system tissues make up this substance. Cancer immunotherapy comes in various forms, such as cytokines and vaccines, adoptive cell therapies, oncolytic viruses, tumor-infecting viruses, and others.
Cancer Immunotherapy Global Market Report 2023 provides data on the global cancer immunotherapy market such as market size, growth forecasts, segments and geographies, competitive landscape including leading competitors’ revenues, profiles and market shares. The cancer immunotherapy market report identifies opportunities and strategies based on market trends and leading competitors’ approaches.